Literature DB >> 17633049

The pathogenesis of malignant ascites.

J Tamsma1.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17633049     DOI： 10.1007/978-0-387-48993-3_6

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN： 0927-3042


× No keyword cloud information.
  13 in total

1.  Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study.

Authors:  Klaus Pietzner; Ignace Vergote; Armando Santoro; Radoslav Chekerov; Frederik Marmé; Per Rosenberg; Holger Martinius; Hilke Friccius-Quecke; Jalid Sehouli
Journal:  Med Oncol       Date:  2014-11-04       Impact factor: 3.064

2.  Respiratory distress due to malignant ascites palliated by hyperthermic intraperitoneal chemotherapy.

Authors:  Marijn Marinus Leonardus van den Houten; Thijs Ralf van Oudheusden; Michael Derek Philip Luyer; Simon Willem Nienhuijs; Ignace Hubertus Johannes Theodorus de Hingh
Journal:  World J Gastrointest Surg       Date:  2015-03-27

3.  The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.

Authors:  Markus M Heiss; Pawel Murawa; Piotr Koralewski; Elzbieta Kutarska; Olena O Kolesnik; Vladimir V Ivanchenko; Alexander S Dudnichenko; Birute Aleknaviciene; Arturas Razbadauskas; Martin Gore; Elena Ganea-Motan; Tudor Ciuleanu; Pauline Wimberger; Alexander Schmittel; Barbara Schmalfeldt; Alexander Burges; Carsten Bokemeyer; Horst Lindhofer; Angelika Lahr; Simon L Parsons
Journal:  Int J Cancer       Date:  2010-11-01       Impact factor: 7.396

4.  Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study.

Authors:  Jalid Sehouli; Klaus Pietzner; Pauline Wimberger; Ignace Vergote; Per Rosenberg; Andreas Schneeweiss; Carsten Bokemeyer; Christoph Salat; Giovanni Scambia; Dominique Berton-Rigaud; Armando Santoro; Andrés Cervantes; Olivier Trédan; Christophe Tournigand; Nicoletta Colombo; Alexander S Dudnichenko; Anneke Westermann; Hilke Friccius-Quecke; Florian Lordick
Journal:  Med Oncol       Date:  2014-06-26       Impact factor: 3.064

Review 5.  Surgical technology and pharmacology of hyperthermic perioperative chemotherapy.

Authors:  Paul H Sugarbaker; Kurt Van der Speeten
Journal:  J Gastrointest Oncol       Date:  2016-02

6.  Peritoneal carcinomatosis of colorectal origin: Incidence, prognosis and treatment options.

Authors:  Yvonne L B Klaver; Valery E P P Lemmens; Simon W Nienhuijs; Misha D P Luyer; Ignace H J T de Hingh
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

7.  Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer.

Authors:  Fausto Petrelli; Karen Borgonovo; Veronica Lonati; Stefano Elia; Sandro Barni
Journal:  Target Oncol       Date:  2012-11-30       Impact factor: 4.493

8.  Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer.

Authors:  V Harding; E Fenu; H Medani; R Shaboodien; S Ngan; H K Li; R Burt; N Diamantis; M Tuthill; S Blagden; H Gabra; C E Urch; S Moser; R Agarwal
Journal:  Br J Cancer       Date:  2012-08-09       Impact factor: 7.640

9.  Review of catumaxomab in the treatment of malignant ascites.

Authors:  Martin Sebastian
Journal:  Cancer Manag Res       Date:  2010-11-08       Impact factor: 3.989

10.  Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab).

Authors:  Diane Seimetz
Journal:  J Cancer       Date:  2011-05-25       Impact factor: 4.207
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.